Loading clinical trials...

Multicenter Observational Study of PSC and IgG4-SC in China | Clinical Trials | Clareo Health

UNKNOWN

Multicenter Observational Study of PSC and IgG4-SC in China

Multicenter Study of Clinical Characteristics and Management of Primary Sclerosing Cholangitis and IgG4-related Sclerosing Cholangitis in China.

NCT05463445•RenJi Hospital

View on ClinicalTrials.gov

Summary

The investigators aimed to collect demographic features and clinical outcomes in patients diagnosed with PSC and IgG4-SC by utilizing participants database from multiple medical centers across Mainland China. Cross-sectional studies will focus on characterizing clinical presentations and validating diagnostic and prognostic models on Chinese PSC and IgG4-SC patients.

Eligibility

Age

18 - 85 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age above 18 years old,
•Male or Female,
•Patients admitted in our medical centers which met the PSC criteria according to The European Association for the Study of the Liver Clinical Practice Guidelines "Management of cholestatic liver diseases" in 2009; or patients diagnosed with IgG4-SC which met initially using the Japan Pancreas Society criteria and confirmed using HISORt criteria.

Exclusion Criteria

•Female subjects who is pregnant, breastfeeding or is considering being pregnant during the study;
•History of other malignancies, including hematological tumors, solid tumors except hepatobiliary system;
•History of infectious diseases, including hepatis A, B, C, E and tuberculosis.

Locations (1)

RenJi Hospital

Shanghai, Shanghai Municipality, China

Key Dates

Start Date

July 1, 2022

Primary Completion Date

December 31, 2022

Completion Date

July 31, 2023

Last Updated

July 19, 2022

Enrollment

1,000

ESTIMATED participants

Conditions

Primary Sclerosing CholangitisIgG4-related Sclerosing Cholangitis

Interventions

Only observation

OTHER

Contacts

Min Lian, MD, PhD

CONTACT

+8615800744783 sophialian24@163.com

Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients

NCT04753996

Primary Sclerosing CholangitisPSC+1 more

View study

RECRUITING

A-LiNK: Improving Outcomes in Autoimmune Liver Disease

NCT05750498

Autoimmune HepatitisPrimary Sclerosing Cholangitis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 19, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Multicenter Observational Study of PSC and IgG4-SC in China

Inclusion Criteria

Exclusion Criteria

Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients

A-LiNK: Improving Outcomes in Autoimmune Liver Disease

Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin

Liver Cirrhosis Network Cohort Study

S-adenosylmethionine (SAMe) in Patients With Primary Sclerosing Cholangitis (PSC)

Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)